The basic research of molecular taget therapy HSP90a and HIF-1a for oral squamous cell carcinoma
| Project/Area Number |
24792236
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | ＦＯＸＣ２ / 分子標的治療薬 / ＥＧＦＲｖⅢ / 口腔癌 / 扁平上皮癌 / 転移 / 浸潤 / 分子標的 / 細胞周期 |
|---|
| Outline of Final Research Achievements |
FOXC2 expresson was asspciated with pattern of invasion, N classification, VEGF-A and VEGF-C expression.FOXC2 overexpression was also associated with poor disease specific survival rate. FOXC2 expression may be involved in the potential of invasion and progression of iral tongue squamous cell carcinoma via FOXC2-VEGF signaling pathway.
The expression levels of p16 and EGFRvⅢ in oral cancer patients to elucidate the association between the these expression and the efficacy of the cetuximab treatment was performed. EGFRvⅢexpression was detected in 43.8% in the oral cancer patients and p16 in 18.8%. The significant relation was detected only between EGFRvⅢ expression and the treatment efficacy with cetuximab.
|
Report
(4 results)
Research Products
(8 results)
